Answer: Retrovir (zidovudine, or AZT) was approved in 1987.
Answer: Developed by Roche, Invirase (saquinavir) was the sixth antiretroviral and first protease inhibitor approved by the FDA.
Answer: The breakthrough news was announced at the 11th International AIDS Conference, which took place in Vancouver in 1996.
Answer: Combivir (zidovudine/lamivudine) was approved by the FDA in 1997 and greatly simplified HIV treatment at the time.
Answer: HIV treatment was recommended for people with HIV with fewer than 500 CD4s. Today, the current guidelines recommend treatment for all people living with HIV regardless of CD4 count.
Answer: Atripla (efavirenz/tenofovir disoproxil fumarate/emtricitabine) was approved in 2006.
Answer: In 2011, the HIV Prevention Trials Network (HPTN 052) study demonstrated that the use of ARVs by HIV-positive heterosexual men and women cut the chance that their HIV-negative partner would contract the virus by roughly 96%. HPTN 052 and other studies prove that people living with HIV on effective treatment do not sexually transmit the virus, which is known as U=U, or Undetectable Equals Untransmittable.
Answer: The FDA approved Truvada as a tool to prevent HIV in 2012.
Answer: Cabenuva (cabotegravir/rilpivirine) was approved in early 2021. It is administered every four weeks.
Answer: Trogarzo. Both Norvir and Tybost are used to boost the levels of other antiretrovirals in the blood.
Click here to learn more about HIV treatment.